G57321FI
| Organisms | Evidence |
|---|---|
| Fasciola hepatica (liver fluke) | |
| Toxocara canis (dog roundworm) | |
| Echinococcus granulosus | |
| Oryctolagus cuniculus (rabbit) | |
| Ovis aries (sheep) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| ST6GALNAC2 | CMP-Neu5Ac |
|
para-nitrophenol | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
| ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol |
| Pathway Name | Organism |
|---|---|
| E.coli O101 | Escherichia coli |
| E.coli O103 | Escherichia coli |
| E.coli O107 | Escherichia coli |
| E.coli O112ab | Escherichia coli |
| E.coli O112ac | Escherichia coli |
| E.coli O116 | Escherichia coli |
| E.coli O117 | Escherichia coli |
| E.coli O125ab | Escherichia coli |
| E.coli O127 | Escherichia coli |
| E.coli O128ab-H27 | Escherichia coli |
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 32502344 | Dual-Probe Approach for Mass Spectrometric Quantification of MUC1-Specific Terminal Gal/GalNAc In Situ | Sun B | 2020 Jun 05 |
|
| 32119947 | H-type lectins – Structural characteristics and their applications in diagnostics, analytics and drug delivery | Pietrzyk-Brzezinska AJ | 2020 Jun 01 |
|
| 32726826 | The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges | Trinchero A | 2020 Jul 29 |
|
| 32578997 | Cysteine Aminoethylation Enables the Site-Specific Glycosylation Analysis of Recombinant Human Erythropoietin using Trypsin | Lippold S | 2020 Jul 21 |
|
| 32681153 | Large-scale site-specific mapping of the O-GalNAc glycoproteome | Yang W | 2020 Jul 17 |
|
| 32535887 | Bariatric surgery decreases oxidative stress and protein glycosylation in patients with morbid obesity | Carmona-Maurici J | 2020 Jul 13 |
|
| 32005975 | C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer | Lee PC | 2020 Jan 31 |
|
| 31932717 | Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3 | de las Rivas M | 2020 Jan 13 |
|
| 32161592 | Activation of the C-Type Lectin MGL by Terminal GalNAc Ligands Reduces the Glycolytic Activity of Human Dendritic Cells | Zaal A | 2020 Feb 25 |
|
| 32034693 | Givosiran: First Approval | Scott LJ | 2020 Feb 08 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025